Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Injections of medicine into the middle of the eye (intravitreal injections) are commonly used
in a multitude of retinal diseases. We are looking for new treatments that may be beneficial
in treating retinal disease and improving patients' vision.
Infliximab (Remicade) is a genetically engineered antibody against a molecule in the body
called TNF-α. It neutralizes the effects of TNF-α by binding to it. Intravenous Infliximab
has been used for inflammatory arthritic conditions and Crohn's disease since 1998. We do not
know if infliximab injections into the eye are safe. We are performing this pilot study to
determine if they can be safe.